Daily Stock Analysis, BPMC, Blueprint Medicines Corp, priceseries

Blueprint Medicines Corp. Daily Stock Analysis
Stock Information
Open
75.91
Close
75.13
High
77.84
Low
74.33
Previous Close
75.33
Daily Price Gain
-0.20
YTD High
92.00
YTD High Date
Dec 11, 2017
YTD Low
27.83
YTD Low Date
Jan 3, 2017
YTD Price Change
46.18
YTD Gain
159.52%
52 Week High
92.00
52 Week High Date
Dec 11, 2017
52 Week Low
26.38
52 Week Low Date
Dec 23, 2016
52 Week Price Change
46.70
52 Week Gain
164.26%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 7. 2017
71.56
Dec 14. 2017
75.86
7 Trading Days
6.00%
Link
Company Information
Stock Symbol
BPMC
Exchange
NasdaqGS
Company URL
http://www.blueprintmedicines.com
Company Phone
617-374-7580
CEO
Jeffrey W. Albers
Headquarters
Massachusetts
Business Address
38 SIDNEY STREET, SUITE 200, CAMBRIDGE, MA 02139
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001597264
About

Blueprint Medicines Corp. is a biopharmaceutical company, which engages in developing of kinase inhibitors for genomically defined subsets of cancer patients. It has developed a platform that combines genomics with a novel library of kinase inhibitors, enabling the development of potent highly selective compounds against clear genomic driver targets. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker and Alexis Borisy in October 2008 and is headquartered in Cambridge, MA.

Description

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. Its lead drug candidates include BLU-285, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V, abnormally active receptor tyrosine kinases for patients with systemic mastocytosis, a disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor; and BLU-554, which is in Phase I clinical trials an orally available, potent, selective, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies, as well as candidates as inhibitors of neurotrophic tyrosine receptor kinase (NTRK) and predicted NTRK resistant mutants. In addition, the company is developing treatments that target cancer and rare genetic diseases. The company has agreements with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.